Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00680485
Recruitment Status : Terminated
First Posted : May 20, 2008
Last Update Posted : January 20, 2017
Information provided by (Responsible Party):

April 14, 2008
May 20, 2008
January 20, 2017
June 2007
October 2007   (Final data collection date for primary outcome measure)
Safety and tolerability of GSK580416 doses determined from clinical safety and tolerability data from all adverse event reporting, 12-lead ECGs, vital signs, nursing/physician observation, and safety laboratory tests
Same as current
Complete list of historical versions of study NCT00680485 on Archive Site
Pharmacokinetics of GSK580416 as determined by AUC, Cmax, tmax, half-life, and Ct.
Same as current
Not Provided
Not Provided
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416
A Three Part Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeat Escalating Oral Doses of GSK580416; the Safety, Tolerability, and Pharmacokinetics of GSK580416 Following a Loading Dose Regimen; and the Effect of Ketoconazole on the Pharmacokinetics of GSK580416
This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses, a loading dose/maintenance dose regimen of GSK580416 and when co administered with ketoconazole, a PGP/CYP3A4 inhibitor.
A three part study in healthy adult subjects to evaluate the safety, tolerability and pharmacokinetics of repeat escalating oral doses of GSK580416; the safety, tolerability, and pharmacokinetics of GSK580416 following a loading dose regimen; and the effect of ketoconazole on the pharmacokinetics of GSK580416
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Bacterial Infection
  • Infections, Bacterial
Drug: GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
October 2007
October 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy adults (as determined by medical evaluation including history, physical exam, vital signs, laboratory tests, and cardiac monitoring)
  • Aged 18-60yrs, with BMI of 19-31kg/m2.
  • Females must be of non-childbearing potential.
  • QTc < 450 msec at screening.
  • Subjects must be able to give consent and comply with restrictions of study.

Exclusion Criteria:

  • Clinically significant CNS, cardiac, pulmonary, metabolic, renal, hepatic or GI condition or history that may place the subject at an unacceptable risk or may interfere with absorption, distribution, metabolism, or excretion of drug.
  • Positive urine drug screen.
  • Positive urine test for alcohol.
  • Positive HIV or Hep B and/or C assay.
  • History of regular tobacco use within 3 monts prior to screening or cotinine levels indicative of smoking at screening.
  • History of regular alcohol consumption (14 units/week for women and 21 units/week for men).
  • History of drug abuse or dependence within 12 months of study.
  • Participation in another drug trial within 30 days of first dose.
  • Exposure to more than 4 new chemical entities within 12 months of first dose.
  • Use of prescription and non-prescription drugs including vitamins, dietary supplements, herbals within 7 days of first dose or St. John's Wort within 28 days of the first dose.
  • Consumption of red wine, Seville oranges, grapefruit, or grapefruit juices within 14 days of first dose.
  • Donation of blood in excess of 500 mL within 56 days of dosing. No blood donation is allowed 30 days prior to study participation.
  • A positive immunochemical fecal occult blood test at screening.
  • History of sensitivity to any of the study medications.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • History of orthostatic hypotension or orthostatic hypotension at screening.
Sexes Eligible for Study: All
18 Years to 64 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP